28-02-2025
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Feb 28, 2025--
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or 'Norum's disease'.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharma company dedicated to the development of innovative biomedicines for the most severe inflammatory diseases for which there is no effective or existing treatment, even in the rarest indications. The company accelerates the development of breakthrough therapies thanks to in-depth expertise in lipid science and a technological platform based on recombinant apoA-I. ABIONYX Pharma is committed to radically improving the results of sepsis treatments and intensive care.
CONTACT: NewCap
Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
[email protected]
+33 (0)1 44 71 98 53NewCap
Media relations
Arthur Rouillé
+33 (0)1 44 71 00 15
KEYWORD: MICHIGAN EUROPE UNITED STATES NORTH AMERICA FRANCE
SOURCE: ABIONYX Pharma
Copyright Business Wire 2025.
PUB: 02/28/2025 01:30 AM/DISC: 02/28/2025 01:30 AM
